Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343402 | 0.92 | SRC (0.52) | CA2PKML3MBTL1SRCTDP1 | |
| SCHEMBL5087200 | 0.86 | PKM (0.47) | CA2PKML3MBTL1SRCTDP1 | |
| SCHEMBL5087201 | 0.86 | PKM (0.47) | CA2PKML3MBTL1SRCTDP1 | |
| SCHEMBL11560938 | 0.85 | PKM (0.65) | PKML3MBTL1SRCTDP1ELANE | |
| SCHEMBL1726270 | 0.85 | MEN1 (0.56) | PKML3MBTL1SRCTDP1MEN1 | |
| SCHEMBL17359428 | 0.85 | L3MBTL1 (0.46) | CA2PKMCA12CA1CA4 | |
| SCHEMBL9818167 | 0.84 | SRC (0.48) | PKML3MBTL1SRCTDP1ELANE | |
| SCHEMBL32667934 | 0.84 | SRC (0.48) | PKML3MBTL1SRCTDP1ELANE | |
| SCHEMBL27042268 | 0.82 | SRC (0.47) | PKML3MBTL1SRCTDP1ELANE | |
| SCHEMBL17491620 | 0.82 | SRC (0.47) | PKML3MBTL1SRCTDP1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895068-B2 | Nanoparticle composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889103-B2 | Diagnostic agent composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PHAX, PIK3CA | CA2 1362/4885PKM 329/4885CA12 173/4885 |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PIK3CA, PTEN | CA2 2456/4885PKM 603/4885CA12 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.